Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2149-2157

  Bone, Henry G ^a   Bolognese, Michael A ^b   Yuen, Chui Kin ^c   Kendler, David L ^d   Wang, Huei ^e   Liu, Yu ^e   San Martin, Javier ^e  

^a Michigan Bone and Mineral Clinic   (United States)

^b Bethesda Health Research Center   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE;

ADULT; APPENDICITIS; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITOMETRY; BONE DENSITY; BONE STRUCTURE; BONE TURNOVER; BREAST DISEASE; CELLULITIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY DISEASE; HIP; HUMAN; HUMAN EXPERIMENT; HYPOCALCEMIA; INFECTION; INFLUENZA; LIMB PAIN; LUMBAR SPINE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROTOXICITY; NORTH AMERICA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; PYELONEPHRITIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RASH; REPRODUCTIVE TOXICITY; RHINOPHARYNGITIS; SEPSIS; SHOULDER PAIN; SINUSITIS; SORE THROAT; STREPTOCOCCUS INFECTION; URINARY TRACT INFECTION;

EID: 45149124792     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2814     Document Type: Article

References (32)

1. Anonymous 1997 Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 7:1-6
2. NIH Consensus Development Panel on Osteoporosis Prevention Data 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
3. Riggs BL, Khosla S, Melton 3rd LJ 2002 Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302
4. Hofbauer LC, Kuhne CA, Viereck V 2004 The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268-275
5. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R 2001 Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation. J Biol Chem 276:8836-8840
6. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
9. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:997-1001
10. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the Proc Natl Acad Sci USA 97:1566-1571
11. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400
12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
13. Ominsky MS Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE 2007 The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporosis Int 18:1073-1082
14. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ 2003 Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18: 852-858
15. Campagnuolo G, Bolon B, Feige U 2002 Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 46:1926-1936
16. Ross AB, Bateman TA, Kostenuik PJ, Ferguson VL, Lacey DL, Dunstan CR, Simske SJ 2001 The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 12:583-588
17. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
18. WHO Study Group 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. In:WHOTechnical Report Series. Geneva: World Health Organ Tech Rep Ser 843:1-129
19. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM 2001 Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
20. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES, Study of Osteoporotic Fractures Research Group 2005 Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787-2793
21. Beck TJ, Ruff CB, Warden KE, Scott Jr WW, Rao GU 1990 Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol 25:6-18
22. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 22:1832-1841
23. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338:485-492
24. Cohen SB, Dore RK, Lane NE, Ory PA, Pederfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark Ron behalf of the Denosumab RA Study Group 2008 Denosumab treatment effects on structural damage, BMD, and bone turnover in rheumatoid arthritis: a randomized, placebo-controlled clinical trial. Arthritis Rheum 58:1299-1309
25. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AHG, Peterson MC, Fan M, Kinsey A, Jun S 2007 Active-controlled phase 2 study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25:4431-4437
26. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066
27. Miller RE, Branstetter D, Armstrong A, Kennedy B, Jones J, Cowan L, Bussiere J, Dougall WC 2007 Receptor activator of NF-κB ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 179:266-274
28. Stolina M, Guo J, Faggioni R, Brown H, Senaldi G 2003 Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109:347-354
29. National Osteoporosis Foundation 2003 Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation
30. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston Jr CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA, Force AOT 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544-564
31. The World Health Organization Fracture Risk Assessment Tool. www.shef.au.uk/FRAX
32. Simon JA 2005 Does osteopenia warrant treatment? Menopause 12:639-648